Therefore, we initiated a retrospective cohort study to evaluate the survival benefits of AICT in patients with advanced‐stage EGFR‐mutated NSCLC following progression on frontline EGFR‐TKI treatment. Here, EGFR is linked to non-small cell lung carcinoma.